Aura Biosciences insider increases holdings with RSU and option grants
Rhea-AI Filing Summary
Form 4 filing overview – Aura Biosciences, Inc. (AURA)
On 06/18/2025, Aura Biosciences filed a Form 4 reporting insider transactions by director David Michael Johnson. On 06/17/2025, the reporting person received two equity awards under the company’s 2021 Stock Option and Incentive Plan:
- 13,000 Restricted Stock Units (RSUs) – issued at no cost; each RSU converts 1:1 into common shares. Vesting occurs in full on the earlier of 17 Jun 2026 or the next annual shareholder meeting, contingent on continued service.
- 17,000 stock options – exercise price $6.18, same vesting schedule as the RSUs, expiring 17 Jun 2035.
Post-transaction ownership reported:
- Direct: 179,167 common shares
- Indirect: 289,672 shares held through two irrevocable trusts (75,000 each) and Velocity Capital Management LLC (139,672), entities where Johnson exercises trustee or sole-member control.
- Total beneficial ownership: 468,839 shares.
The filing indicates acquisitions only; no dispositions were reported. The grants reinforce insider alignment through additional unvested equity that will mature within roughly one year, providing potential signaling value to investors regarding management’s confidence in the company’s prospects.
Positive
- Director-only acquisitions: 13,000 RSUs and 17,000 at-the-money options granted with no concurrent sales.
- Increased insider alignment: Total beneficial ownership now stands at 468,839 shares, enhancing skin-in-the-game.
Negative
- None.
Insights
TL;DR – Director added 30,000 new equity units, boosting total stake to ~469k shares; insider buying generally interpreted as positive alignment.
This Form 4 shows pure acquisitions: 13k RSUs (zero cost) and 17k options struck at $6.18. With no sales, Johnson’s direct stake rises to 179,167 shares, complemented by nearly 290k indirect shares. The single-year vesting horizon concentrates incentive around forthcoming operational milestones and the next AGM, suggesting confidence in near-term value creation. The option strike is close to current market levels (price not provided in filing), minimizing option overhang and indicating fair-market issuance rather than deeply out-of-the-money grants. Overall, the filing is modest in size relative to Aura’s float but directionally positive for sentiment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,000 | $0.00 | -- |
| Grant/Award | Common Stock | 13,000 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Velosity Capital Management LLC is an entity that the Reporting Person is the sole member of. This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
